Fierce Biotech News & Reports
Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on Fierce Biotech as their must-read source for the latest news, analysis and data in the world of biotech ...
Fierce Biotech Layoff Tracker 2024
6 days ago · Dec. 11 - Nvelop Therapeutics / Chroma Medicine: As part of their merger to form new Boston-based biotech nChroma Bio, both Nvelop and Chroma have shed an undisclosed number of employees.Story ...
Introducing Fierce Biotech's 2024 Fierce 15
One of our Fierce 15 honorees dove deep into the ocean for inspiration from the sea squirt to develop new human therapeutics. Another thought the adorable 13-lined ground squirrel, with its polka ...
A look at the R&D landscape in obesity, led by GLP-1s - Fierce …
Mar 19, 2024 · If you’re feeling like overnight obesity became the indication du jour, you’re not alone. Novo Nordisk was granted approval for semaglutide to be marketed as Wegovy for chronic weight ...
Genentech inks $850M upfront deal for Regor's CDK inhibitors
Sep 30, 2024 · Genentech is paying $850 million upfront for Regor Pharmaceuticals’ portfolio of CDK inhibitors, taking ownership of a breast cancer candidate that has shown signs of single-agent efficacy in ...
Biotech | Fierce Biotech
Oct 28, 2024 · Humacyte’s tissue-based Symvess is designed to be universally implantable for patients facing the loss of a limb.
MedTech | Fierce Biotech
A look back at our top stories of 2024 sees them fall into two major themes: promise, and a realignment of expectations.
Vertex pain data: Combo results, Vicodin miss and stellar safety
Oct 21, 2024 · Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid painkiller combines with ibuprofen and why the prospect failed to match ...
Ono inks $700M biobuck deal to bag preclinical LigaChem ADC
Oct 10, 2024 · Ono Pharmaceutical has bought a seat in a quiet corner of the congested antibody-drug conjugate (ADC) space, agreeing to pay LigaChem Biosciences up to $700 million for a potential first-in-class ...
New cell therapy biotech emerges from the lab of George Church
Sep 19, 2024 · From science fiction to reality . GCTx is based around TFome, a cellular programming platform built to “plug and play”—that is, to deliver off-the-shelf induced pluripotent stem cell (iPSC ...